Archive for the ‘Prevention’ category

Undetectable viral load and HIV prevention: what do gay and bi men need to know?

June 14, 2017

What does undetectable mean? What about undetectable viral load and HIV transmission? And if I’m living with HIV, can I use “undetectable viral load” as an HIV prevention strategy?

From thebody.com

Risk of HIV transmission is virtually eliminated when people living with HIV are consistently taking effective HIV medication, (known as antiretroviral therapy or ARVs). It’s well-verified by research, and backed up by many years of real world observation: There have been no cases of transmission in couples where the HIV-positive partner was on meds and had “undetectable” viral load test results for at least six months.

But what does this mean for gay and bi men making decisions about sex, whether in ongoing partnerships, casual dating or anonymous encounters? Get the answers on thebody.com.

Regional resource for men who havd sex with men

June 8, 2017

m4mHealthySex.org is a joint effort between the HIV Prevention and Care Project and the Pitt Men’s Study at the Graduate School of Public Health, University of Pittsburgh. Our goal is to provide up-to-date sexual health information for men who have sex with men. You can use the site to find free STD testing in your area (including free HIV testing). You can also locate PrEP providers based on a zip code search. Other site features include an up-to-date blog of news and information related to sexual health and listings of regional health services (including HIV treatment specialists).

Mental health care is key to ending AIDS

May 24, 2017

From Advocate.com

Research shows a strong correlation between mental health disorders and living with HIV or AIDS, a correlation that is often overlooked. According to the National Institutes of Health, people with HIV have an increased risk for developing mood, anxiety, and cognitive disorders and are twice as likely to live with depression as those who do not have HIV. A 2010 U.K. study showed that one-third of HIV-positive men who participated in the survey met the criteria for a post-traumatic stress disorder diagnosis.  

For those living with HIV or AIDS, depression is more than just mental hell — it can be a silent killer. Studies show that if people living with HIV feel stigmatized or suffer from mental illness, they are less likely to take their medication properly, which not only puts their own health at risk by not suppressing the individuals’ viral load, but also raises the likelihood that they will pass HIV on to others. Individuals living with HIV and depression are also more likely to think about suicide or even attempt to take their own lives. 

Despite what we know about the connection between mental health and HIV/AIDS, too few people living with HIV or AIDS, and those invested in their health and happiness, are getting the mental health support they need. That is why we are proud to announce the opening of the state-of-the-art GMHC Carl Jacobs Mental Health Clinic, which will allow us to incorporate innovative treatment and counseling into our service model. Services will be available to adult New Yorkers of all sexual orientations, gender identities, and income levels, regardless of HIV status.

Past traumas, stress, depression, reduced self-esteem, and other challenges can be grueling to deal with. We aim to offer holistic services that address not only our clients’ mental health issues, but their social, spiritual and health concerns as well. Meanwhile, the ability to reach more HIV-negative people with HIV-preventive interventions and mental health services will help us decrease new HIV infections. 

Read the full article.

Find PrEP providers in your area with the PrEP Locator

March 3, 2017

From m4mHealthSex.org

There’s a lot of research now regarding PrEP (Pre-Exposure Prophylaxis) and how taking this daily anti-viral medication can keep you from becoming infected with HIV. The problem is that most gay men don’t want to ask their doctor about it and don’t know how else they can get it.

truvadaBut now you can use a free online tool called PrEP Locator to find PrEP providers near you. The locator is a national directory of providers that you can search by entering your zip code. It’s also accessible on your smart phone as well as your computer.

Note too that in some cases, providers can also help with the cost of PrEP.

PrEP Locator is presented by Emory University, in partnership with M•A•C AIDS Fund.

If you live in the Pittsburgh area, you can also find local resources here.

For more information about PrEP and how it can help protect you from becoming infected with HIV, go to our Website: https://m4mhealthysex.org/what-is-prep/.

 

 

NASTAD: People living with HIV on antiretroviral therapy (ART) do not transmit the virus

March 1, 2017

From LGBTweekley.com

nastad-300x195WASHINGTON, D.C. – NASTAD (National Alliance of State & Territorial AIDS Directors), a leading non-partisan non-profit association that represents public health officials who administer HIV and hepatitis programs in the U.S. and around the world, published a new statement affirming that durably virally suppressed people living with HIV on antiretroviral therapy (ART) do not sexually transmit the virus. The statement accelerates NASTAD’s longstanding work to end HIV and promote policies and public health practice grounded in science.

”The science is clear that people living with HIV with a sustained undetectable viral load do not transmit the virus to others. What’s also clear is that we have the tools to end the HIV epidemic and HIV-related stigma and make new infections a thing of the past. Today, we tackle a major part of this work by raising awareness about the latest science of HIV transmission risk,” remarked NASTAD Executive Director Murray Penner.

Read the full article.

Professor of sociology Matt G. Mutchler’s interview: HIV prevention and treatment issues within the African American community

February 13, 2017

From csudhnews.com

Professor of sociology Matt G. Mutchler’s research over the past 20 years into HIV prevention and treatment issues, especially within the African American community, has garnered him more than 15 external research awards and respect as an expert in the field. In addition to serving as a faculty member at California State University, Dominguez Hills, he is currently a visiting professor with the Center for AIDS Prevention and Study at University of California, San Francisco, and director of community-based research with AIDS Project Los Angeles.

Mutchler’s more recent work addresses sexual communication among African-American gay and bisexual males and their close friends, and other sexual health issues related to gay men. He also investigates HIV treatment adherence programs.

Mutchler brings his expertise in community-based research to the CSUDH’s Urban Community Research Center (UCRC), where he serves as director. The multi-disciplinary, sociology-based applied research center focuses on the needs, problems and solutions that arise in urban areas. The center also offers CSUDH students hand-on research experience as they collaborate with CSUDH faculty, and a number of governmental, community-based, and university/research institutions, such as AIDS Project Los Angeles (APLA), Charles R. Drew University, Spectrum, REACH LA, and the RAND Corporation.

Mutchler recently shared insights about his studies and findings, the challenges and rewards of conducting his research within the African American community, and his latest work.

Read the interview with Professor Mutchler on csudhnews.com.

The first large-scale clinical trial of a long-acting injectable drug for HIV prevention begins

December 22, 2016

From NewsMedical.net

injectable-prepThe first large-scale clinical trial of a long-acting injectable drug for HIV prevention began today. The study, sponsored by the National Institutes of Health, will examine whether a long-acting form of the investigational anti-HIV drug cabotegravir injected once every 8 weeks can safely protect men and transgender women from HIV infection at least as well as the anti-HIV medication Truvada taken daily as an oral tablet. If injectable cabotegravir is found to be effective for HIV pre-exposure prophylaxis, also known as PrEP, it may be easier for some people to adhere to than daily oral Truvada, the only licensed PrEP regimen. Truvada consists of the two anti-HIV drugs emtricitabine and tenofovir disoproxil fumarate.

“We urgently need more HIV prevention tools that fit easily into people’s lives,” said Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH. “Although daily oral Truvada clearly works for HIV prevention, taking a daily pill while feeling healthy can be difficult for some people. If proven effective, injectable cabotegravir has the potential to become an acceptable, discreet and convenient alternative for HIV prevention.”

Read the full article.